Innovent Biologics, Inc.
Innovent Biologics, Inc. has 2 licensing announcements in this dataset, dated 2026-05-28 to 2026-07-14.
- Country / operating region
- China
- Ticker
- 01801.HK
- Headquarters
- 查無
- Founded
- 2011
- Business
- Biopharmaceutical research, development, manufacturing and commercialization
- Website
- www.innoventbio.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| Twelve early-stage and de novo oncology programs | 查無 | 查無 | 查無 | 2026-05-28 |
| IBI355; SP001 | CD40L | antibody | phase1 | 2026-07-14 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| IBI354 | PHASE3 | NCT07377643 | RECRUITING | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 2026-02-25 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-05-28 | Pfizer Inc. | Twelve early-stage and de novo oncology programs | USD 650m | 查無 | ≤ USD 9850m | 查無 | — |
| 2026-07-14 | Spero Therapeutics, Inc. | IBI355; SP001 | 查無 | 查無 | 查無 | ≈ USD 1100m | — |
| Counterparty | Territory | Royalties |
|---|---|---|
| Pfizer Inc. | Worldwide for four programs; ex-Greater China for four; global co-development with US/Europe co-commercialization for four | Up to double-digit royalties on licensed products; US and Europe profit sharing for co-developed programs. |
| Spero Therapeutics, Inc. | Worldwide excluding mainland China, Hong Kong, Macau and Taiwan | Tiered royalties on net sales in licensed territories. |
Asia ADC assets and licensing deals
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無